Fluticasone Furoate

證據等級: L5

預測適應症: 10 個

Fluticasone Furoate: From COPD and Asthma to Atopic Eczema

One-Sentence Summary

Fluticasone furoate (FF) is a next-generation inhaled corticosteroid with exceptionally high glucocorticoid receptor affinity, globally approved as the core component of Trelegy Ellipta (FF/UMEC/VI) and Relvar Ellipta (FF/VI) for COPD and asthma — though it holds no current registration in Singapore. The TxGNN model predicts it may be effective for Atopic Eczema, with 11 clinical trials and 2 publications currently supporting this direction. Critically, all existing trial evidence derives from the closely related compound fluticasone propionate (FP) rather than fluticasone furoate itself, and no topical skin formulation of FF currently exists — making this a compelling but formulation-constrained repurposing hypothesis.

Quick Overview

Item	Content
Original Indication	Not registered in Singapore; globally approved for COPD and asthma (as Trelegy Ellipta / Relvar Ellipta)
Predicted New Indication	Atopic Eczema
TxGNN Prediction Score	99.98%
Evidence Level	L3
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on established pharmacology, fluticasone furoate belongs to the fluorinated corticosteroid class and is a highly potent glucocorticoid receptor (GR) agonist with a receptor relative affinity (RRA) of approximately 2,989 — roughly 29 times that of dexamethasone. Its clinical efficacy in COPD and asthma has been established through landmark Phase 3 trials including IMPACT and FULFIL, where FF-containing regimens significantly reduced exacerbation rates, improved FEV₁, and demonstrated a reduction in all-cause mortality. This positions FF as a high-potency, long-residence ICS with proven systemic anti-inflammatory credibility.

Atopic eczema is driven by a Th2-dominant inflammatory cascade involving cytokines such as IL-4, IL-5, IL-13, TSLP, and IL-33, with downstream mast cell activation and impaired skin barrier function. Glucocorticoid receptor agonism — FF's primary mechanism — can suppress these cytokine pathways at the transcriptional level, theoretically interrupting the self-reinforcing inflammation cycle seen in chronic atopic dermatitis. This mechanistic overlap is precisely why topical corticosteroids are the first-line treatment for eczema flares.

The class-effect support is substantial: the structurally related compound fluticasone propionate (FP), marketed as Cutivate, has been tested in multiple Phase 4 RCTs enrolling hundreds of patients with atopic dermatitis, and consistently serves as the active comparator benchmark against newer agents such as tacrolimus and pimecrolimus. However, a critical limitation distinguishes FF from FP: fluticasone furoate currently exists only in inhaled formulations (Ellipta dry powder inhaler). No approved or investigational topical skin preparation of FF exists, meaning any direct repurposing to atopic eczema would require developing an entirely new dosage form — a substantial pharmaceutical and regulatory hurdle.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00689832	Phase 4	Completed	487	Large multicentre double-blind RCT in children ≥2 years with moderate-to-severe AD; tacrolimus 0.03% vs fluticasone propionate 0.005% ointment — FP serves as the efficacy benchmark establishing class standard of care
NCT00690105	Phase 4	Completed	577	Large multicentre double-blind RCT in adults with facial AD ("red face" lesions); tacrolimus 0.1% vs fluticasone propionate ointment for 3–6 weeks — establishes FP's efficacy in moderate-to-severe facial AD
NCT00616538	Phase 4	Completed	121	Randomized investigator-blind controlled pilot study in paediatric subjects; EpiCream barrier cream vs fluticasone propionate 0.05% as mid-strength steroid standard of care
NCT01915914	Phase 4	Completed	107	Randomized open-label study evaluating FP 0.05% cream administered twice weekly (intermittent regimen) combined with daily moisturisation to reduce relapse risk in paediatric patients with stabilised AD
NCT00119158	Phase 4	Completed	90	Exploratory double-blind vehicle-controlled paired study evaluating concomitant use of pimecrolimus cream 1% and Cutivate cream 0.05% in patients with severe AD lesions
NCT00546000	Phase 4	Completed	56	Multi-centre open-label study of Cutivate (FP) lotion 0.05% assessing HPA axis effects when used to treat atopic dermatitis in infants
NCT01772056	Phase 3	Terminated	54	Double-blind RCT of twice-weekly FP 0.05% cream for 16-week maintenance treatment to reduce relapse in mild-to-moderate AD in children; terminated prior to completion
NCT03742414	Phase 2	Active, not recruiting	398	SEAL (Stopping Eczema and ALlergy) study: proactive sequential skin care (EpiCream + FP cream) vs reactive AD therapy in infants with early-onset AD to prevent the allergic march and food allergy
NCT04706559	N/A	Completed	98	Probiotic supplementation in children with AD assessed by SCORAD index; fluticasone used as background standard-of-care comparator rather than primary intervention
NCT03594565	Early Phase 1	Completed	13	Small exploratory case series of topical nasal steroids for CGM sensor-related skin reactions in children with type 1 diabetes; extremely small scale and non-standard AD trial design

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19571596	2009	Review	Neuroimmunomodulation	Reviews systemic effects of intranasal corticosteroids on the HPA axis; discusses cumulative corticosteroid burden in patients using ICS for allergic rhinitis, asthma, and atopic dermatitis concurrently — relevant to the safety assessment of FF class effects
40066386	2025	Case Report	Indian Journal of Otolaryngology and Head and Neck Surgery	Case study of allergen immunotherapy (AIT) in autoimmune settings; contextualises AIT use in atopic dermatitis and interactions with corticosteroid therapy

Singapore Market Information

Fluticasone furoate holds no product registrations with the Health Sciences Authority (HSA) of Singapore. The drug is not currently marketed in Singapore in any dosage form.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Research Question

Rationale: While the TxGNN model assigns a very high prediction score (99.98%) and class-effect evidence from fluticasone propionate is well-established in atopic dermatitis, fluticasone furoate itself has no topical skin formulation, no direct clinical trials in atopic eczema, and no Singapore regulatory registration. The evidence level of L3 reflects indirect, class-effect support rather than FF-specific data, making this a scientifically plausible but pre-translational hypothesis requiring substantial development work before clinical evaluation is feasible.

To proceed, the following is needed:

Topical formulation development: A dermal formulation of fluticasone furoate must be developed from scratch — no such product currently exists in any market
FF-specific preclinical skin data: Direct evidence of FF's pharmacokinetics and efficacy in skin tissue models to confirm transdermal delivery and local GR activation
Mechanism of action confirmation: Full MOA data from DrugBank/literature to formally document GR-binding in skin relative to Th2 pathway suppression
HPA axis risk assessment: Given FF's exceptional GR potency (RRA ~2,989), any topical formulation will need rigorous systemic absorption and adrenal suppression studies
Head-to-head design against FP: Any future trial must justify FF over the already-established fluticasone propionate (Cutivate) in terms of potency, safety profile, or patient benefit
Singapore regulatory pathway: HSA registration of fluticasone furoate in at least one formulation would be a prerequisite for local development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.